Copyright: ©Author(s) 2026.
World J Gastroenterol. Jun 14, 2026; 32(22): 118323
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.118323
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.118323
Figure 1 Study timeline of patients in resection and chemotherapy groups, indicating treatment phases and assessment points.
A: Study timeline for patients undergoing upfront surgery; B: Study timeline for patients undergoing resection after neoadjuvant chemotherapy; C: Study timeline for patients receiving palliative chemotherapy; D: Flow diagram showing patient enrolment and allocation in this study. ctDNA: Circulating tumor DNA; f/u: Follow up.
- Citation: Jung K, Lee J, Jang D, Ahn J, Kim B, Yang S, Kim JH, Youn Y, Lee JC, Kim J, Hwang JH. Serial circulating tumor DNA as a biomarker for monitoring and prognostication in patients with pancreatic cancer. World J Gastroenterol 2026; 32(22): 118323
- URL: https://www.wjgnet.com/1007-9327/full/v32/i22/118323.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i22.118323